<p>Alan R Lifson<sup>1,8*</sup>, Elizabeth M Krantz<sup>2,8</sup>, Lynn E Eberly2,8, Matthew J Dolan<sup>3</sup>, Vincent C Marconi<sup>4</sup>, Amy C Weintrob<sup>8,5</sup>, Nancy F Crum-Cianflone<sup>8,6</sup>, Anuradha Ganesan<sup>7,8</sup>, Patricia L Grambsch<sup>2,8</sup>, Brian K Agan<sup>8</sup> and the Infectious Disease Clinical Research Program (IDCRP) HIV Working Group<sup>8</sup></p>
Among HIV-infected persons initiating highly active antiretroviral therapy (HAART), early CD4+ lymphocyte count increases are well described. However, whether CD4+ levels continue to increase or plateau after 4-6 years is controversial.
To address this question and identify other determinants of CD4+ response, we analyzed data for 1,846 persons from a prospective HIV military cohort study who initiated HAART, who had post-HAART CD4+ measurements, and for whom HIV seroconversion (SC) date was estimated.
CD4+ count at HAART initiation was ≤ 200 cells/mm3 for 23%, 201-349 for 31%, 350-499 for 27%, and ≥500 for 19%. The first 6 months post-HAART, the greatest CD4+ increases (93-151 cells) occurred, with lesser increases (22-36 cells/year) through the first four years. Although CD4+ changes for the entire cohort were relatively flat thereafter, HIV viral load (VL) suppressors showed continued increases of 12-16 cells/year. In multivariate analysis adjusting for baseline CD4+ and post-HAART time interval, CD4+ responses were poorer in those with: longer time from HIV SC to HAART start, lower pre-HAART CD4+ nadir, higher pre-HAART VL, and clinical AIDS before HAART (P < 0.05).
Small but positive long-term increases in CD4+ count in virally suppressed patients were observed. CD4+ response to HAART is influenced by multiple factors including duration of preceding HIV infection, and optimized if treatment is started with virally suppressive therapy as early as possible.
*Corresponding author: Alan R Lifson firstname.lastname@example.org
CLICK HERE FOR FULL-TEXT PDF OF THE JOURNAL ARTICLE
© 2011 Lifson et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.